Lipigon Q1 2025: 64.5% Subscription Rate in the Rights Issue - Redeye

Redeye comments on Lipigon’s first quarter report 2025. With a replenished cash position, Lipigon aims to enrol the last patient in its phase II study in Q2 and obtain the first results in Q4. There has also been some new data from Marea’s phase II study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1112526/lipigon-q1-2025-64-5-subscription-rate-in-the-rights-issue?utm_source=finwire&utm_medium=RSS